WA1

Vantage Data Centers Experienced Unprecedented Growth in 2023 Driven by AI and Cloud Demand Globally; Secured $10 Billion in Incremental Funding

Retrieved on: 
Wednesday, January 31, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131123978/en/
    In 2023, Vantage Data Centers entered two new markets (London and Taipei), broke ground on seven campuses and opened 10 facilities across the globe.
  • Pictured is a rendering of the company’s LHR1 London campus that will include 55MW across two data centers.
  • (Photo: Business Wire)
    Throughout 2023, Vantage leveraged these new investments to serve customers in key markets, supporting the development of digital infrastructure and technology hubs globally.
  • “It has been an exceptional year for Vantage’s growth with unprecedented demand for data center capacity around the globe, underpinned by the significant funding from our investors.

"Natural Immunity" from Omicron is Weak and Limited, Study Finds

Retrieved on: 
Wednesday, May 18, 2022

SAN FRANCISCO, May 18, 2022 /PRNewswire/ -- In unvaccinated people, infection with the Omicron variant of SARS-CoV-2 provides little long-term immunity against other variants, according to a new study by researchers at Gladstone Institutes and UC San Francisco (UCSF), published today in the journal Nature.

Key Points: 
  • In experiments using mice and blood samples from donors who were infected with Omicron, the team found that the Omicron variant induces only a weak immune response.
  • To find the answer, the team of researchers first examined the effect of Omicron in mice.
  • Compared to an ancestral strain of SARS-CoV-2 and the Delta variant, Omicron led to far fewer symptoms in the mice.
  • Samples from WA1-infected animals could neutralize Alpha and, to a lesser degree, the Beta and Delta virusbut not Omicron.

Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants

Retrieved on: 
Sunday, March 20, 2022

Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.

Key Points: 
  • Sorrentos designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals.
  • Sorrento intends to develop and seek EUA approval of this next-generation mRNA vaccine in Mexico and other developing countries.
  • These changes result in enhanced transmissibility and breakthrough cases in the presence of antibodies induced by vaccination with the wild-type SARS-CoV-2 spike mRNA vaccines.
  • This novel designer chimeric mRNA vaccine may offer a powerful strategy to develop mRNA vaccines with universal protection against SARS-CoV-2 and its major VOCs.

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

Retrieved on: 
Friday, February 11, 2022

The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.

Key Points: 
  • The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.
  • The study results showed similar activity of Veklury against the variants and an early ancestral A lineage isolate detected in Seattle, WA (WA1 strain).
  • Further characterization confirmed that none of the few identified nsp12 mutations prevalent in some of the SARS-CoV-2 variants affects the virus susceptibility to Veklury.
  • Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.